we first identified that CHAF1B upregulation in both HCC tissues and sorafenib-resistant cell lines, with elevated expression correlating significantly with poor patient prognosis, particularly in sorafenib-treated cohorts. This evidence concerns the gene CHAF1B and hepatocellular carcinoma.